Analyst Expectations for CymaBay Therapeutics’s Future
Over the past 3 months, 4 analysts have published their opinion on CymaBay Therapeutics (NASDAQ:CBAY) stock. These analysts…
Piper Sandler Maintains Overweight on CymaBay Therapeutics, Raises Price Target to $19
Piper Sandler analyst Yasmeen Rahimi maintains CymaBay Therapeutics (NASDAQ:CBAY) with a Overweight and raises the price target from $12 to $19.
Why Baudax Bio Shares Are Trading Higher By 60%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session
Gainers
Baudax Bio, Inc. (NASDAQ: BXRX) shares surged 59.7% to $5.03 after the company announced the outcome of its first interim analysis in a Phase II trial of BX1000 for neuromuscular blockade in patients undergoing elective surgery.
Why CymaBay Therapeutics Shares Are Rising
CymaBay Therapeutics Inc (NASDAQ: CBAY) shares are trading higher by 9.30% to $7.22 Tuesday morning. The company priced a public offering of common stock and pre-funded warrants at $7 per share and $6.999 per warrant.
What Else?
CymaBay Therapeutics Announced Collaboration with Kaken Pharmaceutical to Develop and Commercialize Seladelpar in Japan for Primary Biliary Cholangitis; Kaken to Make Upfront Payment To Cymabay Of ~$34M Plus Milestone Payments Up To ~$128.4M And Royal…
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) announced today that it has entered into a collaboration and license agreement with Kaken Pharmaceutical Co., Ltd. ("Kaken") for the development and commercialization in Japan of CymaBay's investigational drug seladelpar for the treatment of primary biliary cholangitis ("PBC").
CymaBay Therapeutics Q3 EPS $(0.28) Beats $(0.30) Estimate
CymaBay Therapeutics (NASDAQ:CBAY) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.30) by 6.67 percent. This is a 15.15 percent increase over losses of $(0.33) per share
Earnings Scheduled For November 14, 2022
Companies Reporting Before The Bell
• Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly loss at $1.49 per share on revenue of $3.68 million.
Earnings Scheduled For August 11, 2022
Companies Reporting Before The Bell
• Magic Software (NASDAQ:MGIC) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million.
Earnings Outlook For CymaBay Therapeutics
CymaBay Therapeutics (NASDAQ:CBAY) is set to give its latest quarterly earnings report on Thursday, 2022-08-11. Here's what investors need to know before the announcement.
Recap Of Monday’s Biotech Catalysts – End Of the Day Summary
The U.S. Food and Drug Administration (FDA) has cleared the Eledon Pharmaceuticals’ (NASDAQ:ELDN) Investigational New Drug (IND) application…